Acute Urticaria In A Patient With COVID-19: Obstacle Of Treatment

A 48-year-old female patient with relevant past medical history for diabetes mellitus, hypertension, hypothyroidism. There is neither any history for allergy nor a family history of hereditary allergy. She was on metformin with vildagliptin and a combination of bisoprolol and hydrochlorothiazide for a considerable length of time. In March 2021, she admitted with manifestations of dry cough, fever, with rapid onset of deterioration. After an itemized examination including chest CT and testing for Coronavirus, she was diagnosed with SARS-CoV-2 infection. Days after, her state became worsened. She was treated with Ceftriaxone injection, Gemifloxacin, Rivaroxaban, and salbutamol. She goes forward adequately, with 4 days of fever and dry cough, followed by 5 days of anosmia and ageusia from which she wholly improved. On day +13 of disease progression, afterward resolution of the previous symptoms, quickly diffusion Pinkish urticarial plaques developed in numerous positions on her body: face, trunk, abdomen, and limbs (Figure. 1). She has not received any non-steroidal anti-inflammatory drugs or ACE inhibitors. As a symptomatic treatment, only an antihistaminic drug was taken Cetirizine 10 mg tablet twice a day. The cutaneous manifestation was partially controlled within forty-eight hours. She well-ordered to keep the guidelines of home isolation concerning SARS-CoV-2. Overall, her condition is good in this respect.